Target

CD33

Myeloid cell surface antigen CD33

18open trials
31trials in total
28publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
1 Jan 2028· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Universal CAR-T Cells Targeting AML
30 Jun 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
1 May 2027· EARLY_PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
31 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
4 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system.
30 Oct 2026· Immunotherapy advances· PUBMED
Publication
Correction: Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial.
26 Oct 2026· Experimental hematology & oncology· PUBMED
Publication
Developing a Dual-Targeting CD33/CD70 CAR T-Cell Strategy Against Acute Myeloid Leukemia to Overcome Tumor Heterogeneity.
2 Oct 2026· Cancers· PUBMED
Publication
Auer Rod-Like Inclusions in Myeloma Plasma Cells With Aberrant CD34, CD117, and CD33 Expression.
24 Sept 2026· EJHaem· PUBMED
Publication
Enhanced CD33 CAR-NK cells secreting anti-CD73scFv overcome adenosine-mediated immunosuppression and improve anti-AML efficacy.
1 Sept 2026· Journal for immunotherapy of cancer· PUBMED
Publication
Multifunctional anti-CD33 antibody- and polydopamine-coated curcumin-indocyanine green nanoparticles for in vitro cytotoxic effects against leukemia cells.
27 Jul 2026· International journal of pharmaceutics· PUBMED
Publication
CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk.
17 Jul 2026· Nature communications· PUBMED
Publication
Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin.
23 Jun 2026· Journal of clinical medicine· PUBMED
Trial
Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
10 Jun 2026· PHASE1 · RECRUITING· CTGOV
Publication
Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330.
10 Jun 2026· Investigational new drugs· PUBMED
Trial
Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia
1 Jun 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Crystal structure of the CD33/Fab-10C8 complex elucidates the mechanism of antibody antagonism in HBV-induced immunosuppression.
29 May 2026· Journal of biomedical science· PUBMED
Publication
CD33 expression combined with D15-MRD positivity identifies poor prognosis in children with ETV6::RUNX1-positive ALL.
29 May 2026· Annals of hematology· PUBMED
Publication
Toothache and Alzheimer's Disease: A Mendelian Randomization Study of the NAAG-CD33 Neuroimmune Axis.
26 May 2026· Journal of pain research· PUBMED
Publication
Triptolide Reduces Cholesterol Synthesis and Alleviates Neuroinflammation by Inhibiting CD33 in Alzheimer's Disease Development and Progression.
22 May 2026· Biology· PUBMED
Publication
CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.
12 May 2026· Nature medicine· PUBMED
Publication
Active Rac1-Mediated Bone Marrow Retention Enhances CD33 CAR-T Cell Efficacy Against CD33+ Leukemia Cells.
30 Apr 2026· FASEB journal : official publication of the Federation of American Societies for Experimental Biology· PUBMED
Publication
Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin.
30 Apr 2026· International journal of molecular sciences· PUBMED
Publication
CD33 Isoform Splicing Dysregulation: A Molecular Determinant of Microglial Dysfunction in Alzheimer's Disease Pathology.
29 Apr 2026· Molecular neurobiology· PUBMED
Publication
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results.
23 Apr 2026· Haematologica· PUBMED
Publication
A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.
23 Apr 2026· Blood· PUBMED
Trial
Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML
1 Apr 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia.
1 Apr 2026· Cancer research communications· PUBMED
Trial
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
26 Mar 2026· PHASE1 · RECRUITING· CTGOV
Trial
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
2 Mar 2026· PHASE1_PHASE2 · RECRUITING· CTGOV

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error